SCO1 Inhibitors
SCO1 Inhibitors are a class of compounds that can directly or indirectly decrease the functional activity of SCO1. This protein is involved in various biological processes influenced by several signaling pathways. One such pathway includes those regulated by protein kinase C (PKC), an enzyme inhibited by Staurosporine. By inhibiting PKC, Staurosporine indirectly disrupts SCO1 activity by reducing necessary phosphorylation events. Genistein, a tyrosine kinase inhibitor, can decrease SCO1 activity when SCO1's function is associated with tyrosine phosphorylation. Genistein prevents this phosphorylation, disrupting the associated signaling pathways.
The inhibitors LY294002 and Wortmannin, targeting the phosphatidylinositol 3-kinase (PI3K) pathway, can lead to decreased SCO1 activity. The PI3K/Akt pathway is known to regulate cellular metabolism, a key process for SCO1 functionality. Rapamycin, an mTOR inhibitor, disrupts metabolic processes essential for SCO1 activity, leading to its decreased activity. MEK inhibitors such as U0126, PD98059, Trametinib, and Selumetinib can affect SCO1 indirectly by blocking the MAPK/ERK pathway, which could be influencing SCO1's activity. Similarly, SB203580 and SP600125 disrupt the p38 MAPK and JNK pathways respectively, which may also be involved in regulating SCO1's function. Lastly, BAY 11-7082, an inhibitor of NF-κB activation, can disrupt metabolic processes essential for SCO1 activity, leading to its decreased function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including PKC. As SCO1 activity is dependent on phosphorylation, the compound can lead to decreased activity of SCO1 by inhibiting PKC and subsequently reducing phosphorylation events. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein inhibits tyrosine kinases, which are involved in the phosphorylation processes of various proteins. As SCO1 requires tyrosine phosphorylation for its activity, Genistein's action can decrease SCO1 activity by disrupting these necessary phosphorylation processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can disrupt the PI3K/Akt pathway. Since SCO1 plays a role in cellular metabolism, which is regulated by the PI3K/Akt pathway, LY294002 can decrease SCO1 activity by inhibiting this pathway and thus disturbing the metabolic processes necessary for SCO1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a regulator of cellular metabolism and protein synthesis. By inhibiting mTOR, Rapamycin can disrupt the metabolic processes essential for SCO1 activity, leading to decreased SCO1 activity. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB203580 is a p38 MAPK inhibitor that can disrupt the p38 MAPK pathway. If SCO1's activity is regulated via this pathway, SB203580 can lead to decreased SCO1 activity by inhibiting the pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can disrupt the JNK pathway. If SCO1's activity is regulated via this pathway, SP600125 can lead to decreased SCO1 activity by inhibiting the pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that can disrupt the MAPK pathway. If SCO1's activity is influenced by this pathway, PD98059 can lead to decreased SCO1 activity by blocking the pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that can disrupt the PI3K/Akt pathway. SCO1, playing a role in cellular metabolism regulated by PI3K/Akt pathway, can see decreased activity with Wortmannin due to the inhibition of this pathway. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation. Since NF-κB is involved in regulating metabolic processes, its inhibition can lead to decreased SCO1 activity as the metabolic processes necessary for SCO1 activity are disrupted. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that disrupts the MAPK/ERK pathway. Given that SCO1's activity might be influenced by this pathway, Trametinib can lead to decreased SCO1 activity by blocking the pathway. | ||||||